Min 2006.
Methods | Design: 12 weeks, double‐blind, randomised, placebo‐controlled, parallel group study |
Participants |
Population: 43 patients Inclusion criteria: FEV1/FVC ≤ 0.70, FEV1 ≥ 30% predicted |
Interventions |
1. Tiotropium 18 mcg once daily 2. Placebo once daily |
Outcomes | FEV1, FVC, FEV1/FVC, FEV1%, safety |
Notes |